Consensus for FY24 EPS is $4.60. Reaffirms FY24 revenue growth view of 1%-2%, consensus $1.14B.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PBH:
- Prestige Consumer Healthcare Inc. Reports Third Quarter Fiscal 2024 Results
- PBH Upcoming Earnings Report: What to Expect?
- Insight Pharmaceuticals Issues Voluntary Nationwide Recall of TING® 1% Tolnaftate Athlete’s Foot Spray Antifungal Spray Liquid Due to the Presence of Benzene
- Prestige Consumer’s Insight voluntarily recalls two lots of TING 1% spray
- Prestige Consumer Healthcare Inc. to Release Fiscal 2024 Third Quarter Earnings Results